Lung Cancer Drug Pipeline Update Lists All 243 Drugs for

[dadstimeon]

Lung Cancer and Gives You a Progress Analysis on Each One of Them

http://www.genengnews.com/news/bnitem.a ... NEWSML.xml

2/16/2006 9:50:00 AM EST

Research and Markets (http://www.researchandmarkets.com/reports/c32989) has announced the addition of Lung Cancer Drug Pipeline Update 2006 to their offering.

According to American Cancer Society approximately 175 000 people will be diagnosed and 160 000 people died by lung cancer every year in the US. Over 800,000 people worldwide dies of non-small cell lung cancer (NSCLC) each year. More people die of lung cancer than of colon, breast, and prostate cancers combined. According to analysts, the NSCLC drug market is predicted to exceed $4 billion within a 5-7 year period. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012, Aventis' Taxotere (docetaxel), Bristol-Myers Squibb's Paraplatin (carboplatin) and Eli Lilly's Gemzar (gemcitabine). In a recent guideline the expert panel of the ASCO has updated their clinical practice guidelines for the treatment of NSCLC. In the guideline of 2004 Iressa has been recommended as third line treatment of patients with locally advanced or metastatic NSCLC after failure of both platinum-based and docetaxel chemotherapies. There are today no less than 234 emerging therapeutics targeting lung cancer, from early preclinical to Phase III clinical studies.

Lung Cancer Drug Pipeline Update lists all 243 drugs for lung cancer and gives you a progress analysis on each one of them. Read more below how Lung Cancer Drug Pipeline Update is organized:

Developmental stage Contains in total 243 lung cancer drugs in development:

-- 27 marketed drugs

-- 16 projects in Phase III

-- 112 projects in Phase II

-- 36 projects in Phase I

-- 43 projects in Preclinical

Line of treatment Major lines of treatment, including

-- Antiangiogenesis

-- Apoptosis

-- Cell cycle inhibitors

-- Cell therapy

-- Gene therapy

-- Immunomodulator

-- Vaccines

Etc.

Mechanism Includes more than 100 mechanisms of action:

-- Apoptosis agonist

-- DNA topoisomerase inhibitor

-- Microtubule stimulant

-- Beta tubulin antagonist

-- Tubulin antagonist & Microtubule inhibitor

-- Thymidylate synthase inhibitor

-- DNA antagonist

-- ErbB inhibitor

-- Angiogenesis inhibitor

-- DNA topoisomerase ATP hydrolysing inhibitor

-- DNA antagonist

-- Endothelial growth factor receptor kinase inhibitor

-- p21 stimulant

-- Microtubule inhibitor

-- Dihydrofolate reductase inhibitor

Etc.

Target Drug targets for more than 100 drugs is available.

Examples:

-- ATP-binding cassette, subfamily B (MDR/TAP), member 1

-- Caspase 3

-- Colony stimulating factor 2

-- thymidylate synthetase

-- topoisomerase (DNA) I

-- tubulin, beta polypeptide

-- Cyclin G1

-- Cyclin-dependent kinase inhibitor 1A

-- kinase insert domain receptor (a type III receptor tyrosine kinase)

-- mucin 1, transmembrane

-- DNA (cytosine-5-)-methyltransferase 1

-- Epidermal growth factor receptor

-- Eukaryotic translation elongation factor 1 alpha 1

Compound Lists compound name or type of compound:

-- Antibodies

-- Chemical names

-- Enzymes

-- Nucleotides

-- Peptides

-- Proteins

-- Ribozymes

Etc.

Description Progress analysis and review of drug development.

How May Drug Pipeline Update Be of Use?

Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

Find competitors, collaborations partners, M&A candidates etc.

Jump start competitive drug intelligence operations

Excellent starting point for world wide benchmarking

Compare portfolio and therapy focus with your peers

Speed up pro-active in-/outlicensing strategy work

Fast and easy way of tracking drugs using search engines; just one click and you may search World Wide Web and PubMed for any drug with all its synonyms.

Drug Pipeline Update is Delivered to You as a CD-ROM application

Drug Pipeline Update is fitted into a CD-ROM based application, for your intelligent usage:

Smart CD-ROM application, which makes it easy to use and navigate by

Multiple search and sort functions included

Drug data is linked to search engines like Google and PubMed

Direct links to web pages from inside the application

Found information is easily shared with others over email, file export or in print

For more information visit http://www.researchandmarkets.com/reports/c32989

CONTACT:

Research and Markets Laura Wood Fax: +353 1 4100 980 press@researchandmarkets.com